{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:00:38Z","timestamp":1790694038942,"version":"4.1.0"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"unspecified","delay-in-days":28,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Neurol Open"],"accepted":{"date-parts":[[2026,5,9]]},"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:p>Autoimmune neurological diseases affecting the central nervous system, peripheral nervous system and neuromuscular junction are frequently refractory to conventional B-cell-depleting therapies such as CD20-directed monoclonal antibodies, highlighting a need for more effective treatment approaches. Chimeric antigen receptor T (CAR-T) cell therapy, initially developed for haematological malignancy, has been repurposed to more comprehensively deplete pathogenic B-cell and plasma cell populations in autoimmune disease, raising the possibility of durable, treatment-free remission. This scoping review, conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA)-ScR guidelines, examined published clinical studies from January 2023 to January 2026 in which CAR-T cells targeting CD19, CD20 or B-cell maturation antigen were used to treat autoimmune neurological disease, identifying 19 eligible studies. Efficacy signals were most consistent in refractory acetylcholine receptor antibody-positive generalised myasthenia gravis and Aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, with encouraging but more preliminary results reported in multiple sclerosis, Lambert-Eaton myasthenic syndrome, myelin oligodendrocyte glycoprotein antibody-associated disease, chronic inflammatory demyelinating polyneuropathy, stiff-person syndrome and autoimmune encephalitis. Relapse was reported across several conditions, with follow-up generally limited to under two years. The safety profile compared favourably with that seen in oncological CAR-T use, with lower rates of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, although cytopenias, infection and prolonged hypogammaglobulinaemia remain clinically significant, and local immune effector cell-associated toxicity syndrome is an emerging concern not yet formally reported in this population. Current evidence remains limited to small, largely uncontrolled studies with heterogeneous outcome reporting. Adequately powered, longer-term controlled trials are needed before CAR-T therapy can be recommended more broadly in the management of refractory autoimmune neurological disease.<\/jats:p>","DOI":"10.1136\/bmjno-2026-001611","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:37:17Z","timestamp":1790692637000},"page":"e001611","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Chimeric antigen receptor T cell therapy in autoimmune neurological disease: current status of efficacy and safety"],"prefix":"10.1136","volume":"8","clinical-trial-number":[{"clinical-trial-number":"nct07304154","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-2514-5753","authenticated-orcid":false,"given":"Peter","family":"Bradhurst","sequence":"first","affiliation":[{"name":"Clinical Immunology, Concord Hospital, Concord, New South Wales, Australia"},{"name":"Institute of Academic Medicine, Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia"},{"name":"Faculty of Medicine and Health, University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4145-3172","authenticated-orcid":false,"given":"Todd A","family":"Hardy","sequence":"additional","affiliation":[{"name":"Neurology, Concord Repatriation General Hospital, Concord, New South Wales, Australia"},{"name":"The University of Sydney, Camperdown, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9953-9959","authenticated-orcid":false,"given":"Sean","family":"Riminton","sequence":"additional","affiliation":[{"name":"Clinical Immunology, Concord Hospital, Concord, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"2026092907301686000_8.2.e001611.1","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2"},{"key":"2026092907301686000_8.2.e001611.2","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2018-001899"},{"key":"2026092907301686000_8.2.e001611.3","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-024-01139-z"},{"key":"2026092907301686000_8.2.e001611.4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308917"},{"key":"2026092907301686000_8.2.e001611.5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)01126-1"},{"key":"2026092907301686000_8.2.e001611.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2024-226142"},{"key":"2026092907301686000_8.2.e001611.7","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.809754","article-title":"In-Vivo Induced CAR-T Cell for the Potential Breakthrough to Overcome the Barriers of Current CAR-T Cell Therapy","volume":"12","author":"Xin","year":"2022","journal-title":"Front Oncol"},{"key":"2026092907301686000_8.2.e001611.8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.06.027"},{"key":"2026092907301686000_8.2.e001611.9","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41591-025-04171-y","article-title":"BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"32","author":"Vu","year":"2026","journal-title":"Nat Med"},{"key":"2026092907301686000_8.2.e001611.10","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12113445","article-title":"Complications after CD19+ CAR T-Cell Therapy","volume":"12","author":"Penack","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2026092907301686000_8.2.e001611.11","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-023-04041-6","article-title":"Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility","volume":"21","author":"Celichowski","year":"2023","journal-title":"J Transl Med"},{"key":"2026092907301686000_8.2.e001611.12","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1053\/j.seminhematol.2023.02.003","article-title":"Infectious complications of chimeric antigen receptor (CAR) T-cell therapies","volume":"60","author":"Gea-Banacloche","year":"2023","journal-title":"Semin Hematol"},{"key":"2026092907301686000_8.2.e001611.13","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"2026092907301686000_8.2.e001611.14","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0850"},{"key":"2026092907301686000_8.2.e001611.15","doi-asserted-by":"crossref","unstructured":"Chahin N , Sahagian G , Feinberg MH , et al . Twelve-month follow-up of patients with generalized myasthenia gravis receiving bcma-directed mrna cell therapy. Neurology [Preprint] 2024. doi:10.1101\/2024.01.03.24300770","DOI":"10.1101\/2024.01.03.24300770"},{"key":"2026092907301686000_8.2.e001611.16","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1002\/acn3.70167","article-title":"Durability of Response to B-Cell Maturation Antigen-Directed mRNA Cell Therapy in Myasthenia Gravis","volume":"12","author":"Chahin","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"2026092907301686000_8.2.e001611.17","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(23)00194-1"},{"key":"2026092907301686000_8.2.e001611.18","doi-asserted-by":"publisher","DOI":"10.1038\/s44321-024-00043-z"},{"key":"2026092907301686000_8.2.e001611.19","doi-asserted-by":"crossref","unstructured":"Hegelmaier T , Motte J , Walther D , et al . Long-term outcomes of anti-cd19 car t-cell therapy in refractory myasthenia gravis: a case series car t-cells for refractory myasthenia gravis. SSRN [Preprint] 2025. doi:10.2139\/ssrn.5654657","DOI":"10.2139\/ssrn.5654657"},{"key":"2026092907301686000_8.2.e001611.20","doi-asserted-by":"crossref","first-page":"103621","DOI":"10.1016\/j.eclinm.2025.103621","article-title":"Anti-BCMA\/CD19 CAR T cell therapy in patients with refractory generalized myasthenia gravis: a single-arm, phase 1 trial","volume":"90","author":"Zhang","year":"2025","journal-title":"eClinicalMedicine"},{"key":"2026092907301686000_8.2.e001611.21","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2024.101794","article-title":"Anti-CD19 CAR-T cells are effective in severe idiopathic Lambert-Eaton myasthenic syndrome","volume":"5","author":"Wickel","year":"2024","journal-title":"Cell Rep Med"},{"key":"2026092907301686000_8.2.e001611.22","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.neuron.2024.04.014","article-title":"Treatment of concomitant myasthenia gravis and Lambert-Eaton myasthenic syndrome with autologous CD19-targeted CAR T cells","volume":"112","author":"Motte","year":"2024","journal-title":"Neuron"},{"key":"2026092907301686000_8.2.e001611.23","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2024-205103","article-title":"CD19-Directed CAR T Cell Therapy in 4 Patients with Refractory Multiple Sclerosis","volume":"144","author":"Richter","year":"2024","journal-title":"Blood"},{"key":"2026092907301686000_8.2.e001611.24","unstructured":"Pul R . A phase 1, multicenter, single-arm, dose-escalation study of BMS-986353 (CC-97540), a CD19-directed chimeric antigen receptorT cell therapy manufactured using a next-generation process, evaluating safety and tolerability in patients with relapsing orprogressive forms of multiple sclerosis (Breakfree-2). 2025."},{"key":"2026092907301686000_8.2.e001611.25","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.medj.2024.03.002","article-title":"CD19-targeted chimeric antigen receptor T cell therapy in two patients with multiple sclerosis","volume":"5","author":"Fischbach","year":"2024","journal-title":"Med"},{"key":"2026092907301686000_8.2.e001611.26","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.09.020"},{"key":"2026092907301686000_8.2.e001611.27","doi-asserted-by":"crossref","DOI":"10.1038\/s41392-022-01278-3","article-title":"Anti-BCMA CAR T-cell therapy CT103A in relapsed or refractory AQP4-IgG seropositive neuromyelitis optica spectrum disorders: phase 1 trial interim results","volume":"8","author":"Qin","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"2026092907301686000_8.2.e001611.28","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200292","article-title":"CD19-Directed CAR T-Cells in a Patient With Refractory MOGAD","volume":"11","author":"Cabrera-Maqueda","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026092907301686000_8.2.e001611.29","doi-asserted-by":"crossref","first-page":"100704","DOI":"10.1016\/j.medj.2025.100704","article-title":"Anti-BCMA CAR-T cell therapy in relapsed\/refractory chronic inflammatory demyelinating polyneuropathy","volume":"6","author":"Dong","year":"2025","journal-title":"Med"},{"key":"2026092907301686000_8.2.e001611.30","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.hlife.2024.05.005","article-title":"BCMA-CD19 bispecific CAR-T therapy in refractory chronic inflammatory demyelinating polyneuropathy","volume":"2","author":"Zhang","year":"2024","journal-title":"hLife"},{"key":"2026092907301686000_8.2.e001611.31","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(25)00199-1","article-title":"CD19-targeted CAR T-cell therapy for treatment-refractory autoimmune neuropathies","volume":"24","author":"Motte","year":"2025","journal-title":"Lancet Neurol"},{"key":"2026092907301686000_8.2.e001611.32","doi-asserted-by":"crossref","unstructured":"Faissner S , Motte J , Sgodzai M , et al . Successful use of anti-CD19 CAR T cells in severe treatment-refractory stiff-person syndrome. Proc Natl Acad Sci USA 2024;121. doi:10.1073\/pnas.2403227121","DOI":"10.1073\/pnas.2403227121"},{"key":"2026092907301686000_8.2.e001611.33","doi-asserted-by":"crossref","unstructured":"Ayzenberg I , Aloizou A-M , Lohmann C , et al . Anti-CD19 CAR T-Cell Therapy in Advanced Stiff-Person Syndrome and Concomitant Myasthenia Gravis. Neurol Neuroimmunol Neuroinflamm 2025;12. doi:10.1212\/NXI.0000000000200479","DOI":"10.1212\/NXI.0000000000200479"},{"key":"2026092907301686000_8.2.e001611.34","doi-asserted-by":"crossref","first-page":"100776","DOI":"10.1016\/j.medj.2025.100776","article-title":"Chimeric antigen receptor T cells in treatment-refractory DAGLA antibody-associated encephalitis","volume":"6","author":"Hegelmaier","year":"2025","journal-title":"Med"},{"key":"2026092907301686000_8.2.e001611.35","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41409-024-02429-6","article-title":"CAR-T cell therapy embarks on autoimmune disease","volume":"60","author":"Rampotas","year":"2025","journal-title":"Bone Marrow Transplant"},{"key":"2026092907301686000_8.2.e001611.36","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200080","article-title":"CAR-T Cell\u2013Mediated B-Cell Depletion in Central Nervous System Autoimmunity","volume":"10","author":"Gupta","year":"2023","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2026092907301686000_8.2.e001611.37","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s11940-012-0172-y","article-title":"Complications of immunosuppressive\/immunomodulatory therapy in neurological diseases","volume":"14","author":"Nath","year":"2012","journal-title":"Curr Treat Options Neurol"},{"key":"2026092907301686000_8.2.e001611.38","doi-asserted-by":"crossref","first-page":"e424","DOI":"10.1016\/S2665-9913(25)00091-8","article-title":"Local immune effector cell-associated toxicity syndrome in CAR T-cell treated patients with autoimmune disease: an observational study","volume":"7","author":"Hagen","year":"2025","journal-title":"Lancet Rheumatol"},{"key":"2026092907301686000_8.2.e001611.39","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.jaci.2024.11.026","article-title":"Therapeutic B-cell depletion: Mechanisms, clinical applications, and implications for secondary immunodeficiency","volume":"156","author":"Elmoursi","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"2026092907301686000_8.2.e001611.40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2023.10.001"}],"container-title":["BMJ Neurology Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjno-2026-001611","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T14:37:21Z","timestamp":1790692641000},"score":1,"resource":{"primary":{"URL":"https:\/\/neurologyopen.bmj.com\/lookup\/doi\/10.1136\/bmjno-2026-001611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,9,29]]},"published-print":{"date-parts":[[2026,9]]}},"alternative-id":["10.1136\/bmjno-2026-001611"],"URL":"https:\/\/doi.org\/10.1136\/bmjno-2026-001611","relation":{},"ISSN":["2632-6140"],"issn-type":[{"value":"2632-6140","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9]]}}}